TAVI Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

"Market Definition:
The Global TAVI Market size was valued at USD 4.03 billion in 2019 and is predicted to reach USD 12.45 billion by 2030 with a CAGR of 10.8% from 2020-2030. Transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement is a minimally invasive procedure used for the replacement of aortic valve. This procedure is performed for replacing the dysfunctional and damaged heart valve. Echocardiography is used for the diagnosis of valvular heart disease. These procedures help in early recovery of the patient and is generally performed on high-risk patient with aortic stenosis, who cannot undergo surgical valve replacement procedure.
Market Dynamics and Trends
The improvement in healthcare infrastructure as well as huge burden of cardiovascular diseases in developing nations have proliferated the growth of TAVI market. Also, the increased demand of minimally invasive procedures coupled with technological advancement is expected to boost the TAVI market throughout the forecast period.
Increasing popularity of TAVI devices due to favorable reimbursement scenario, reduced hospitalization requirement, low risk of infection and reduced blood loss during the procedure is majorly driving the TAVI market globally. Further, increased geriatric population along with rising healthcare expenditure are also expected to contribute to the market growth. However, lack of facilities and trained healthcare professionals are expected to hamper the growth of TAVI market. On the other hand, lucrative opportunities in emerging economies, rising awareness and advancements in TAVI devices are expected create new opportunities for the market growth in future.
Market Segmentations and Scope of the Study:
The global TAVI market share is analyzed on the basis of procedure, and geography. On the basis of procedure, the market is segmented into Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America holds the lion share of the market and is expected to continue domination the TAVI market throughout the forecast period owing to the presence of developed healthcare infrastructure, increased adoption of TAVI devices and technological advancements in this region.
It is expected that the emerging economies, specifically in the Asia-Pacific region would witness increasing market size owing to increasing accessibility to healthcare facilities, increasing medical tourism, and increasing incidences of cardiovascular disorders in APAC countries.

Competitive Landscape

The TAVI market is highly competitive and consists of many market players. The key market players include Abbott Laboratories, JC Medical, Inc., Meril Life Sciences Pvt. Ltd., Bracco S.p.A. (HLT, Inc.), Boston Scientific Corporation (Symetis SA), JenaValve Technology, Inc., Edwards Lifesciences Corporation, Medtronic plc, Venus Medtech, Inc and NVT AG, among others.
There have been various development taking place in the market and will take place in near future, which will contribute to the growth of TAVI market. For instance, in May 2018, Abbott has announced the treatment with the company's Portico transcatheter aortic valve replacement (TAVR) therapy was associated with excellent clinical outcomes at 30 days, including disabling stroke, low rates of death, and paravalvular leak. Additional benefits observed included reduction in New York Heart Association (NYHA) class severity, low rates of bleeding, and improvements in a six-minute walk test, allowing patients to return to their previous lifestyles and activity faster. Data from the PORTICO I study were presented during EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and showed favorable short-term clinical outcomes for safety and performance – consistent with the Portico CE Mark study results that granted European regulatory approval.

KEY MARKET SEGMENTS:
• Global TAVI market – By Procedure
o Transfemoral Implantation
o Transapical Implantation
o Transaortic Implantation
• Global TAVI market –By Geography
o North America
 U.S.
 Canada
 Mexico
o Europe
 UK
 Germany
 France
 Italy
 Switzerland
 Rest of Europe
o Asia-Pacific
 China
 India
 Japan
 Rest of Asia-Pacific
o RoW
 Israel
 Saudi Arabia
 South Africa
 Brazil
 Remaining Countries"